Please assess the completion status of the following clinical trial:

Trial Title: Furosemide in Early Acute Kidney Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed and written consent by patient or surrogate~* Peripheral or central intravenous catheter~* The presence of early AKI~* 2 or more criteria for the systemic inflammatory response syndrome (SIRS) within 24 hours~* Achieved immediate resuscitation goals~Exclusion Criteria:~* Confirmed or suspected pregnancy~* Age \<18 years~* Stage 4 or greater chronic kidney disease or kidney transplantation~* Acute pulmonary edema requiring urgent use of furosemide or RRT~* Patient is moribund with expected death within 24 hours~* Known or suspected drug allergy to furosemide~* Enrolled in concomitant randomized trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Furosemide (Type: ACTIVE_COMPARATOR): Furosemide intravenous continuous infusion
- Normal Saline (Type: PLACEBO_COMPARATOR): Normal saline titrated continuous intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).